作者
Ariana Harari, Zigui Chen, Ana Cecilia Rodríguez, Allan Hildesheim, Carolina Porras, Rolando Herrero, Sholom Wacholder, Orestis A Panagiotou, Brian Befano, Robert D Burk, Mark Schiffman, Costa Rica HPV Vaccine Trial (CVT) group, Paula González, Roland Herrero, Silvia E Jiménez, Carolina Porras, Ana Cecilia Rodríguez, Allan Hildesheim, Aimée R Kreimer, Douglas R Lowy, Mark Schiffman, John T Schiller, Mark Sherman, Sholom Wacholder, Ligia A Pinto, Troy J Kemp, Mary Sidawy, Wim Quint, Leen-Jan van Doorn, Linda Struijk, Joel M Palefsky, Teresa M Darragh, Mark H Stoler
发表日期
2016/3/15
期刊
The Journal of infectious diseases
卷号
213
期号
6
页码范围
939-947
出版商
Oxford University Press
简介
Background. Results from the Costa Rica Vaccine Trial (CVT) demonstrated partial cross-protection by the bivalent human papillomavirus (HPV) vaccine, which targets HPV-16 and HPV-18, against HPV-31, -33, and -45 infection and an increased incidence of HPV-51 infection.
Methods. A study nested within the CVT intention-to-treat cohort was designed to assess high-risk HPV variant lineage–specific vaccine efficacy (VE). The 2 main end points were (1) long-term incident infections persisting for ≥2 years and/or progression to high-grade squamous intraepithelial lesions (ie, cervical intraepithelial neoplasia grade 2/3 [CIN 2/3]) and (2) incident transient infections lasting for <2 years. For efficiency, incident infections due to HPV-16, -18, -31, -33, -35, -45, and -51 resulting in persistent infection and/or CIN 2/3 were matched (ratio, 1:2) to the more-frequent …
学术搜索中的文章
A Harari, Z Chen, AC Rodríguez, A Hildesheim… - The Journal of infectious diseases, 2016
